Silence Therapeutics (XRP2) Financial Statements
Silence Therapeutics Financial Overview
Silence Therapeutics's market cap is currently $1.10B. The company's EPS TTM is $-3.81; its P/E ratio is -5.18; Silence Therapeutics is estimated to report earnings on November 17, 2026, and the estimated EPS forecast is $-0.10. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 559.00K | $ 43.26M | $ 25.38M | $ 17.65M | $ 12.41M |
| Gross Profit | $ 344.00K | $ 31.45M | $ 15.06M | $ 6.68M | $ 4.96M |
| Operating Income | $ -89.75M | $ -63.32M | $ -49.60M | $ -49.76M | $ -45.81M |
| EBITDA | $ -88.05M | $ -49.12M | $ -49.78M | $ -39.93M | ― |
| Net Income | $ -88.61M | $ -45.31M | $ -43.27M | $ -41.03M | $ -39.41M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 85.11M | $ 117.68M | $ 54.44M | $ 71.14M | $ 73.54M |
| Total Assets | $ 131.44M | $ 161.85M | $ 94.53M | $ 107.50M | $ 96.19M |
| Total Debt | $ 160.00K | $ 93.45K | $ 273.81K | $ 446.00K | $ 137.00K |
| Net Debt | $ -11.12M | $ -96.82M | $ -54.16M | $ -54.37M | $ -73.40M |
| Total Liabilities | $ 69.14M | $ 54.80M | $ 77.12M | $ 85.43M | $ 87.67M |
| Stockholders' Equity | $ 62.30M | $ 107.05M | $ 21.99M | $ 22.07M | $ 8.53M |
| Cash Flow | |||||
| Free Cash Flow | $ -62.33M | $ -54.22M | $ -39.40M | $ -57.59M | $ 7.39M |
| Operating Cash Flow | $ -62.27M | $ -54.05M | $ -39.35M | $ -57.04M | $ 9.19M |
| Investing Cash Flow | $ -47.99M | $ -17.55M | $ 16.43M | $ -20.50M | $ 11.71M |
| Financing Cash Flow | $ 15.00K | $ 113.54M | $ 25.16M | $ 52.58M | $ 41.45M |
Currency in GBP
